FDA starts pilot to help sponsors use novel trial designs

31 August 2018

Nick Paul Taylor / FierceBiotech

The FDA has initiated a pilot program (PDF) to help drug developers use complex innovative trial designs (CID). Sponsors accepted into the four-year pilot will meet twice with the FDA to discuss regulatory approaches to CID. 

Officials at the FDA committed to help advance the use of complex adaptive, Bayesian and otherwise novel clinical trial designs as part of the latest PDUFA agreement. These designs pose new challenges for sponsors such as the need to use simulations to determine trial operating characteristics, and therefore additional regulatory input is beneficial to ensure they meet the FDA’s expectations.

The pilot program is intended to ensure sponsors can access that input. The FDA is asking sponsors with plans to use CID to file to join the program, although it has only committed to accepting up to two applications a quarter. The agency will prioritize trials that rely on simulations and will test drugs that address unmet needs when choosing which applicants to accept. 

The resulting meetings will help the FDA take its stance on CID.

“The goal ... is to provide advice on how a proposed CID approach can be used in a specific drug development program and to promote innovation by allowing FDA to publicly present the trial designs considered through the pilot program, including trial designs for drugs that have not yet been approved by FDA,” the agency wrote. 

Sponsors accepted into the program will hold an initial meeting with the FDA to discuss a CID, and then meet again within 120 days to follow up on the same topic. This input could make it easier for the sponsors to adopt CID, but acceptance into the program isn’t a guarantee the FDA will sign off on a design, nor is a rejection from the pilot an unbreachable barrier to a company running a novel trial. 


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more